Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Up 1,000% in 2020, Is Co-Diagnostics Stock Still a Buy?

By Taylor Carmichael - Dec 10, 2020 at 12:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company has unbelievable top-line growth right now, and has profit margins over 60%. Will the stock continue to ride high once the world is vaccinated?

Co-Diagnostics ( CODX -4.88% ) might be the strongest growth stock in the market right now, with third-quarter revenue up about 50,000%. This is a bit of a misleading statistic, as the company had only $41,000 in revenue at this time last year. Nonetheless, to drive sales from such a tiny base to $21 million is really impressive. And while companies in hypergrowth mode are rarely profitable, Co-Diagnostics is an exception. Indeed, the company reports net margins of 63% so far in 2020.

green bull standing in front of a stock chart shooting higher

Image source: Getty Images.

So here's a company with amazing 50,000% revenue growth, and profit margins superior to Visa. It's not surprising that early investors have enjoyed a beautiful 11-bagger so far in 2020. In fact, we might ask why the stock hasn't gone a lot higher.

Co-Diagnostics has a price-to-sales ratio under 6, and a forward P/E of 6 as well. That's incredibly cheap for a company with skyrocketing sales growth. Why is the stock market unwilling to give this diagnostic company a higher multiple?

Co-Diagnostics has diagnostics for multiple diseases, including one for tuberculosis bacteria, and another test for the Zika virus. But of course in 2020, what's driving all the revenue growth is COVID-19 testing.

The stock market appears skeptical about how much of the company's revenue growth is sustainable. What happens to the COVID-19 testing market if we're all vaccinated against this virus?

Key questions for investors are whether COVID-19 testing will start to decline, and whether Co-Diagnostics can successfully market other products. For now, I'm staying on the sidelines. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
$9.17 (-4.88%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.